These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 21432867)

  • 21. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis.
    Feng S; Agoulnik IU; Truong A; Li Z; Creighton CJ; Kaftanovskaya EM; Pereira R; Han HD; Lopez-Berestein G; Klonisch T; Ittmann MM; Sood AK; Agoulnik AI
    Endocr Relat Cancer; 2010 Dec; 17(4):1021-33. PubMed ID: 20861284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
    Yang JC; Ok JH; Busby JE; Borowsky AD; Kung HJ; Evans CP
    Cancer Res; 2009 Jan; 69(1):151-60. PubMed ID: 19117998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells.
    Xi SC; Tam PC; Brown GM; Pang SF; Shiu SY
    J Pineal Res; 2000 Oct; 29(3):172-83. PubMed ID: 11034115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expression and regulation of androgen receptor in the androgen-independent conversion of prostate cancer cells].
    Wang HF; Liu WJ; Jin J; Zhou LQ; Liang LL; Wang Y; Guo YL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 43(4):490-5. PubMed ID: 21844951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells.
    Ikezoe T; Chen SS; Yang Y; Heber D; Taguchi H; Koeffler HP
    Int J Oncol; 2003 Nov; 23(5):1461-70. PubMed ID: 14532991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A.
    Leiblich A; Cross SS; Catto JW; Pesce G; Hamdy FC; Rehman I
    Prostate; 2007 Dec; 67(16):1761-9. PubMed ID: 17929277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
    Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
    J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
    Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
    Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
    Harper ME; Goddard L; Smith C; Nicholson RI
    Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.
    Park JW; Lee JK; Witte ON; Huang J
    Mod Pathol; 2017 Sep; 30(9):1262-1272. PubMed ID: 28621319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
    Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
    Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
    Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells.
    Pinto JT; Sinha R; Papp K; Facompre ND; Desai D; El-Bayoumy K
    Int J Cancer; 2007 Apr; 120(7):1410-7. PubMed ID: 17205524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
    Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
    Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
    Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.
    Lipianskaya J; Cohen A; Chen CJ; Hsia E; Squires J; Li Z; Zhang Y; Li W; Chen X; Xu H; Huang J
    Asian J Androl; 2014; 16(4):541-4. PubMed ID: 24589459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.
    Chuu CP; Hiipakka RA; Fukuchi J; Kokontis JM; Liao S
    Cancer Res; 2005 Mar; 65(6):2082-4. PubMed ID: 15781616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.